IP Library Granted Patent US 7,094,542
Granted Patent B2
US 7,094,542 · App. 10/245,988 · Granted Aug 22, 2006

Detection of rpoB sequences of Mycobacterium tuberculosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,094,542
App. No.
10/245,988
Granted
Aug 22, 2006
Kind
B2
Abstract

A method of detecting rpoB sequences of Mycobacterium tuberculosis present in a biological sample that includes steps of amplifying the M. tuberculosis rpoB sequence in vitro in a nucleic acid amplification mixture that includes specific disclosed primer sequences, and detecting the amplified sequences using multiple probes that provide sequence information by their specific hybridization to portions of the amplified nucleic acid. Compositions for amplifying and detecting in vitro the rpoB sequences of M. tuberculosis in a sample are disclosed.

Claims (30)

1. A method of detecting rpoB sequences of Mycobacterium tuberculosis present in a biological sample, comprising the steps of:

providing a biological sample containing nucleic acid from M. tuberculosis comprising a rpoB sequence;

amplifying the rpoB sequence in an in vitro nucleic acid amplification reaction mixture comprising at least one polymerase activity, and primers consisting of SEQ ID NO:2 with SEQ ID NO: 3,

to produce amplified nucleic acid containing a rpoB sequence;

optionally fragmenting the amplified nucleic acid;

hybridizing the amplified nucleic acid to at least one detection probe consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4 that hybridizes specifically to M. tuberculosis sequences; and

detecting the amplified nucleic acid hybridized to at least one detection probe by detecting a label associated with the amplified nucleic acid.

2. The method of claim 1 , before the amplifying step, further comprising the steps of:

adding to the biological sample at least one capture oligomer consisting of SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:9 that specifically hybridizes to a M. tuberculosis sequence, and an immobilized nucleic acid that hybridizes to a 3′ tail sequence of the capture oligomer;

hybridizing the nucleic acid from M. tuberculosis , the capture oligomer, and the immobilized nucleic acid to produce a hybridization complex comprising the nucleic acid from M. tuberculosis , the capture oligonucleotide, and the immobilized nucleic acid; and

separating the hybridization complex from other components of the biological sample.

3. The method of claim 1 , wherein the detecting step further uses a detection probe consisting of SEQ ID NO:12.

4. The method of claim 1 , wherein the detecting step uses at least one detection probe consisting of the sequence of SEQ ID NO:4.

5. The method of claim 1 , wherein the detecting step uses a plurality of detection probes in a DNA probe array, wherein at least one detection probe in the array is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.

6. The method of claim 1 , wherein the amplifying step uses primers of SEQ ID NO:2 with SEQ ID NO:3, and a helper oligomer consisting of SEQ ID NO:1.

7. The method of claim 1 , wherein the amplifying step further uses a primer consisting of SEQ ID NO:8, and a helper oligomer consisting of SEQ ID NO:1.

8. The method of claim 1 , wherein the amplifying step further uses primers of SEQ ID NO:10 with SEQ ID NO:11.

9. The method of claim 1 , wherein the amplifying step uses a transcription-mediated amplification reaction mixture.

10. The method of claim 1 , wherein the amplifying step uses a polymerase chain reaction amplification reaction mixture.

11. The method of claim 1 , wherein the fragmenting step comprises chemically fragmenting the amplified nucleic acid and fluorescently labeling fragments of the amplified nucleic acid.

12. A composition for detecting a rpoB sequence of M. tuberculosis , comprising oligonucleotides consisting of SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO: 4.

13. A composition for detecting a rpoB sequence of M. tuberculosis , comprising oligonucleotides consisting of SEQ ID NO:2, SEQ ID NO:3, and at least one detection probe selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.

14. A composition for detecting a rpoB sequence of M. tuberculosis according to claim 12 , further comprising an oligonucleotide consisting of SEQ ID NO:1.

15. A composition for detecting a rpoB sequence of M. tuberculosis according to claim 13 , wherein the detection probe is in a DNA probe array.

16. A composition for detecting a rpoB sequence of M. tuberculosis according to claim 13 , further comprising oligonucleotides consisting of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

17. A kit comprising at least three oligonucleotides, wherein two oligonucleotides consist of SEQ ID NO:2 and SEQ ID NO:3, and at least one other oligonucleotide is selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:4.

18. A composition for detecting a rpoB sequence of M. tuberculosis according to claim 12 , further comprising an oligonucleotide consisting of SEQ ID NO:9.

19. A composition for detecting a rpoB sequence of M. tuberculosis according to claim 13 , further comprising an oligonucleotide consisting of SEQ ID NO:9.

20. The composition according to claim 15 , wherein the DNA probe array detects mutations of the rpoB sequence defined by amino acid substitutions at positions of codons relative to the initiation codon selected from the group consisting of: F505L/L511P/S531C, Q513L, H526D, D516Y, H526Y, L511P, and H526R.

21. The kit according to claim 17 , further comprising an oligonucleotide consisting of SEQ ID NO:9.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →